412 related articles for article (PubMed ID: 30011918)
21. Non-antibody Approaches to Proprotein Convertase Subtilisin Kexin 9 Inhibition: siRNA, Antisense Oligonucleotides, Adnectins, Vaccination, and New Attempts at Small-Molecule Inhibitors Based on New Discoveries.
Nishikido T; Ray KK
Front Cardiovasc Med; 2018; 5():199. PubMed ID: 30761308
[TBL] [Abstract][Full Text] [Related]
22. Angiopoietin-like protein 3 (ANGPTL3) deficiency and familial combined hypolipidemia.
Tarugi P; Bertolini S; Calandra S
J Biomed Res; 2019 Apr; 33(2):73-81. PubMed ID: 29752428
[TBL] [Abstract][Full Text] [Related]
23. The Future of Lipid-lowering Therapy.
Zwol WV; Rimbert A; Kuivenhoven JA
J Clin Med; 2019 Jul; 8(7):. PubMed ID: 31340607
[TBL] [Abstract][Full Text] [Related]
24. Antisense oligonucleotide-mediated inhibition of angiopoietin-like protein 3 increases reverse cholesterol transport in mice.
Bell TA; Liu M; Donner AJ; Lee RG; Mullick AE; Crooke RM
J Lipid Res; 2021; 62():100101. PubMed ID: 34371033
[TBL] [Abstract][Full Text] [Related]
25. ANGPTL3 is a novel HDL component that regulates HDL function.
Yang L; Wang Y; Xu Y; Li K; Yin R; Zhang L; Wang D; Wei L; Lang J; Cheng Y; Wang L; Ke J; Zhao D
J Transl Med; 2024 Mar; 22(1):263. PubMed ID: 38462608
[TBL] [Abstract][Full Text] [Related]
26. Genetic inhibition of angiopoietin-like protein-3, lipids, and cardiometabolic risk.
Gobeil É; Bourgault J; Mitchell PL; Houessou U; Gagnon E; Girard A; Paulin A; Manikpurage HD; Côté V; Couture C; Marceau S; Bossé Y; Thériault S; Mathieu P; Vohl MC; Tchernof A; Arsenault BJ
Eur Heart J; 2024 Mar; 45(9):707-721. PubMed ID: 38243829
[TBL] [Abstract][Full Text] [Related]
27. New Therapeutic Approaches to the Treatment of Dyslipidemia 1: ApoC-III and ANGPTL3.
Kim JY; Kim NH
J Lipid Atheroscler; 2023 Jan; 12(1):23-36. PubMed ID: 36761060
[TBL] [Abstract][Full Text] [Related]
28. ANGPTL3 (Angiopoietin-Like 3) Preferentially Resides on High-Density Lipoprotein in the Human Circulation, Affecting Its Activity.
Kraaijenhof JM; Tromp TR; Nurmohamed NS; Reeskamp LF; Langenkamp M; Levels JHM; Boekholdt SM; Wareham NJ; Hoekstra M; Stroes ESG; Hovingh GK; Grefhorst A
J Am Heart Assoc; 2023 Nov; 12(21):e030476. PubMed ID: 37889183
[TBL] [Abstract][Full Text] [Related]
29. Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis.
Urban D; Pöss J; Böhm M; Laufs U
J Am Coll Cardiol; 2013 Oct; 62(16):1401-8. PubMed ID: 23973703
[TBL] [Abstract][Full Text] [Related]
30. Angiopoietin-like 3 in lipoprotein metabolism.
Kersten S
Nat Rev Endocrinol; 2017 Dec; 13(12):731-739. PubMed ID: 28984319
[TBL] [Abstract][Full Text] [Related]
31. Characterization of three kindreds with familial combined hypolipidemia caused by loss-of-function mutations of ANGPTL3.
Pisciotta L; Favari E; Magnolo L; Simonelli S; Adorni MP; Sallo R; Fancello T; Zavaroni I; Ardigò D; Bernini F; Calabresi L; Franceschini G; Tarugi P; Calandra S; Bertolini S
Circ Cardiovasc Genet; 2012 Feb; 5(1):42-50. PubMed ID: 22062970
[TBL] [Abstract][Full Text] [Related]
32. Gene Silencing of Angiopoietin-like 3 (ANGPTL3) Induced De Novo Lipogenesis and Lipid Accumulation in Huh7 Cell Line.
Rossi I; Marodin G; Lupo MG; Adorni MP; Papotti B; Dall'Acqua S; Ferri N
Int J Mol Sci; 2024 Mar; 25(7):. PubMed ID: 38612519
[TBL] [Abstract][Full Text] [Related]
33. A novel fully human anti-NT-ANGPTL3 antibody from phage display library exhibits potent ApoB, TG, and LDL-C lowering activities in hyperlipidemia mice.
Zhang P; Wang K; Hu T; Xu M; You X; Chen M; Tang X; Hu H; Jiang Y; Zhao W; Tan S
FASEB J; 2024 Jan; 38(1):e23399. PubMed ID: 38174870
[TBL] [Abstract][Full Text] [Related]
34. ANGPTL3 inhibition, dyslipidemia, and cardiovascular diseases.
Luo F; Das A; Khetarpal SA; Fang Z; Zelniker TA; Rosenson RS; Qamar A
Trends Cardiovasc Med; 2024 May; 34(4):215-222. PubMed ID: 36746257
[TBL] [Abstract][Full Text] [Related]
35. Atherosclerosis Residual Lipid Risk-Overview of Existing and Future Pharmacotherapies.
Omari M; Alkhalil M
J Cardiovasc Dev Dis; 2024 Apr; 11(4):. PubMed ID: 38667744
[TBL] [Abstract][Full Text] [Related]
36. Cardiovascular and Metabolic Effects of ANGPTL3 Antisense Oligonucleotides.
Graham MJ; Lee RG; Brandt TA; Tai LJ; Fu W; Peralta R; Yu R; Hurh E; Paz E; McEvoy BW; Baker BF; Pham NC; Digenio A; Hughes SG; Geary RS; Witztum JL; Crooke RM; Tsimikas S
N Engl J Med; 2017 Jul; 377(3):222-232. PubMed ID: 28538111
[TBL] [Abstract][Full Text] [Related]
37. Pre-operative levels of angiopoietin protein-like 3 (ANGPTL3) in women diagnosed with high-grade serous carcinoma of the ovary.
Wong Chong E; Joncas FH; Douville P; Bachvarov D; Diorio C; Calon F; Bergeron AC; Blais J; Leung SOA; Seidah NG; Gangloff A
Lipids Health Dis; 2024 Feb; 23(1):59. PubMed ID: 38414008
[TBL] [Abstract][Full Text] [Related]
38. Advances in Dyslipidaemia Treatments: Focusing on ApoC3 and ANGPTL3 Inhibitors.
Tomlinson B; Wu QY; Zhong YM; Li YH
J Lipid Atheroscler; 2024 Jan; 13(1):2-20. PubMed ID: 38299167
[TBL] [Abstract][Full Text] [Related]
39. The Role of RNA-Targeted Therapeutics to Reduce ASCVD Risk: What Have We Learned Recently?
Miname MH; Rocha VZ; Santos RD
Curr Atheroscler Rep; 2021 Jun; 23(8):40. PubMed ID: 34146170
[TBL] [Abstract][Full Text] [Related]
40. A new dawn for managing dyslipidemias: The era of rna-based therapies.
Macchi C; Sirtori CR; Corsini A; Santos RD; Watts GF; Ruscica M
Pharmacol Res; 2019 Dec; 150():104413. PubMed ID: 31449975
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
